Inspire Medical Systems, Inc. (NYSE: INSP) closed at USD 76.37, reflecting a minor decrease of 0.21 points or -0.27% over the last session. This update matters to stakeholders tracking the medical device sector and to investors assessing short-term volatility.
Company Overview
Inspire Medical Systems, Inc. is a medical technology firm specializing in solutions for patients with obstructive sleep apnea (OSA). Incorporated in 2007 and headquartered in Golden Valley, Minnesota, it develops and commercializes the Inspire system — a neurostimulation technology designed as a minimally invasive treatment for moderate to severe OSA. The system provides closed-loop monitoring of breathing and applies mild hypoglossal nerve stimulation to keep the airway open during sleep.
The company operates in the United States and markets internationally. Its approach aligns with growing demand for innovative, less invasive treatments in sleep medicine and respiratory care.
Stock Performance
On the latest trading day, INSP shares ended at USD 76.37, down 0.21 points (-0.27%). The price range over the past 52 weeks is from USD 70.77 to USD 216.01, reflecting significant volatility and potential trading opportunities. When the current price is near the lower end of this range, some investors may see this as indicative of pressure on valuation, while others may consider it an entry point based on fundamentals.
Trading volume stood at 633,720 shares, which is below the average volume of 1,129,196. Lower-than-average volume can suggest reduced market activity or less investor focus in the short term. Short-lived changes in pricing during low-volume days may carry less predictive significance.
Market Position and Sector
Inspire Medical Systems belongs to the medical devices industry within the broader healthcare sector. Competitive positioning in this segment hinges on innovation, regulatory compliance, and market adoption. Medical device companies often face intensive R&D cycles and regulatory reviews which can affect timelines and costs.
The firm holds a market capitalization of approximately USD 2.26 billion, signaling mid-cap status. This size implies certain liquidity and institutional interest but also exposes the company to market fluctuations that can be more pronounced than that of larger peers.
Governance and Leadership
Timothy P. Herbert serves as Chief Executive Officer. Leadership in a medical technology firm involves strategic decision-making across product development, clinical trials, and market expansion. Herbert’s tenure includes overseeing the regulatory processes, sustaining growth momentum, and ensuring operational stability. Inspire Medical Systems employs 1,246 full-time staff, indicating a sizable organization with diverse clinical, research, and commercial capabilities.
Key Financial Data
- Market Capitalization: USD 2,258,590,513
- Share Price: USD 76.37
- 52-Week Range: USD 70.77 – USD 216.01
- Change: -0.21 (-0.27%)
- Volume: 633,720 shares
- Average Volume: 1,129,196 shares
- Last Dividend: USD 0 — the company does not currently issue dividends, focusing capital on growth and R&D.
These figures suggest the company is in an investment phase. The lack of dividends favors reinvestment over shareholder payouts. Price movements within the 52-week range and average volume levels are significant indicators for both retail and institutional investors.
Trading Details
- Exchange: New York Stock Exchange (NYSE)
- ISIN: US4577301090
- CUSIP: 457730109
- CIK: 0001609550
- IPO Date: May 3, 2018
These identifiers facilitate precise tracking of the stock across financial systems and ensure clarity for regulatory or transactional purposes.
FAQ
- Does Inspire Medical Systems pay dividends? No. The last dividend was USD 0.
- Where is the company headquartered? Golden Valley, Minnesota, USA.
- How many employees work for the company? 1,246 full-time employees.
- When did the company go public? May 3, 2018.
- What is the industry classification? Medical – Devices.
Conclusion
Inspire Medical Systems maintains a focused presence in the medical devices sector with a flagship solution for obstructive sleep apnea. Current stock levels are near the lower end of its 52-week range, accompanied by reduced trading volume. For investors, such conditions may signal caution or opportunity depending on strategy and risk tolerance. Stakeholders should monitor pricing trends, volume shifts, and ongoing innovations as part of their due diligence.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult a licensed advisor.
Official Company Source
For full information about the company, see the link below.
https://www.inspiresleep.com